Previous 10 | Next 10 |
2023-10-19 03:12:00 ET Summary Drugmakers don’t have to dominate a healthcare portfolio. Equity investors should cast a wide net across the sector to find innovation and growth. When pharmaceutical companies conduct tests on new drugs, they typically outsource clinical tria...
2023-10-18 21:49:00 ET Summary After many years of Cumberland’s US Equity ETF portfolios being overweight in the healthcare sector, we are now at our lowest relative market weight for a long time. The economic benefits to the sector from the Covid pandemic are over. The...
2023-10-10 07:16:00 ET Summary European countries have been plagued by a persistent medicine shortage for the past few years. Supply chain disruptions and increased demand are driving the shortfall. There are potential solutions; and one could involve breeding a whole lot more...
2023-09-29 23:45:00 ET Summary A combination of public and private investments in neuroscience, government grants, and charitable donations are helping accelerate a wave of advancements and opportunities in neuroscience. Recent clinical trial success for the second significant, di...
2023-09-28 08:59:14 ET Summary We assess the key factors driving the persistent decline in the share price of Pfizer, one of the world's leading biopharmaceutical companies. We think the stock deserves to trade at a much higher P/E multiple of 20x or more, given its healthy pipeli...
2023-09-27 14:33:22 ET More on iShares U.S. Pharmaceuticals ETF IHE: A Highly Concentrated Portfolio Is Able To Generate Growth Over The Long Run Seeking Alpha’s Quant Rating on iShares U.S. Pharmaceuticals ETF Dividend scorecard for iShares U.S. Pharmaceutica...
2023-09-22 03:30:00 ET Summary Healthcare stocks often serve as powerful painkillers during market declines. While the MSCI World Index fell by 18.1% in 2022, healthcare stocks fell by only 5.4%. Investing effectively in healthcare stocks requires a unique set of skills. ...
2023-08-21 06:18:21 ET Summary iShares U.S. Pharmaceuticals ETF invests almost 80 percent of its assets in its top 10 holdings, and 48.5 percent in just two companies: JNJ and LLY. IHE didn’t generate strong or decent yield, but provided price growth over the long run and h...
2023-08-16 02:28:00 ET Summary Risk-on sentiment and end of pandemic boom have weighed on healthcare. Health insurers and medical device firms have held up better. Growing opportunity in obesity treatments. Tarik Aeta, Global Healthcare Analyst with TD Asset Mana...
2023-08-11 01:45:00 ET Summary The U.S. healthcare system remains a global outlier in both innovation and cost. The U.S. spends twice as much per capita on healthcare versus its developed-country peers yet life expectancy is lower by 6.3 years. Healthcare companies continue to...
News, Short Squeeze, Breakout and More Instantly...
iShares U.S. Pharmaceutical Company Name:
IHE Stock Symbol:
NYSE Market:
2024-06-22 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-31 20:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-29 16:15:00 ET The pharmaceutical market reached a total value of US$1.6 trillion in 2023, according to Statista , up significantly from US$888 billion in 2010. Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as...